Protagenic Therapeutics, Inc. - Common Stock (PTIX)
2.0400
+0.1200 (6.25%)
NASDAQ · Last Trade: Nov 13th, 1:33 PM EST
Detailed Quote
Previous Close
1.920
Open
1.960
Bid
2.010
Ask
2.100
Day's Range
1.960 - 2.114
52 Week Range
1.830 - 15.26
Volume
203,138
Market Cap
3.91M
PE Ratio (TTM)
-0.4789
EPS (TTM)
-4.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
69,476
Chart
About Protagenic Therapeutics, Inc. - Common Stock (PTIX)
Protagenic Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for neurological and psychiatric disorders. The company leverages its proprietary technologies to identify and develop peptides that target specific neuronal pathways, with the aim of addressing unmet medical needs in conditions such as depression and anxiety. Through its research and development efforts, Protagenic Therapeutics seeks to create effective treatment options that can enhance the quality of life for patients suffering from these complex disorders. Read More
NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders, today announced the successful completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study evaluating its lead compound, known as PT00114. The study, conducted in healthy volunteers, was designed to assess the safety and tolerability profile of PT00114 following multiple doses over time. With all healthy volunteers now dosed, the company has achieved a milestone in the clinical development of its proprietary peptide-based therapeutic.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the company announced a key clinical milestone.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
